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The overall CD8 T cell response to human/simian immunodeficiency virus (HIV/SIV) targets a collection of discrete
epitope specificities. Some of these epitope-specific CD8 T cells emerge in the weeks and months following infection and
rapidly select for sequence variants, whereas other CD8 T cell responses develop during the chronic infection phase and
rarely select for sequence variants. In this study, we tested the hypothesis that acute-phase CD8 T cell responses that do not
rapidly select for escape variants are unable to control viral replication in vivo as well as those that do rapidly select for
escape variants. We created a derivative of live attenuated SIV (SIVmac239nef) in which we ablated five epitopes that
elicit early CD8 T cell responses and rapidly accumulate sequence variants in SIVmac239-infected Mauritian cynomolgus
macaques (MCMs) that are homozygous for the M3 major histocompatibility complex (MHC) haplotype. This live attenu-
ated SIV variant was called m3KOnef. Viremia was significantly higher in M3 homozygous MCMs infected with
m3KOnef than in either MHC-mismatched MCMs infected with m3KOnef or MCMs infected with SIVmac239nef.
Three CD8 T cell responses, including two that do not rapidly select for escape variants, predominated during early
m3KOnef infection in the M3 homozygous MCMs, but these animals were unable to control viral replication. These re-
sults provide evidence that acute-phase CD8 T cell responses that have the potential to rapidly select for escape variants in
the early phase of infection are needed to establish viral control in vivo.
The CD8 T cell response to human/simian immunodeficiencyvirus (HIV/SIV) is an aggregate of multiple, discrete epitope-
specific responses. Patterns of T cell immunodominance are often
used to categorize the antiviral efficacy of these individual CD8 T
cell responses. At any given time, the most immunodominant
CD8 T cell response is the highest frequency epitope-specific CD8
T cell response, while other so-called “subdominant” CD8 T cell
responses are present at lower individual frequencies (1). The ear-
liest immunodominant CD8 T cell responses contribute to the
establishment of the viral load set point and define the likelihood
of long-term viral control within an individual (2, 3), while the
subdominant CD8 T cell responses contribute to effective control
of chronic HIV/SIV replication (4, 5). Alternatively, the antiviral
efficacy of CD8 T cells can be defined by whether they select for
immune escape variants rapidly or slowly. Epitopes that do not
rapidly accumulate variants have become attractive as vaccine im-
munogens because they are common in circulating strains of HIV
(6). Nonetheless, it remains unclear to what extent CD8 T cell
responses specific for epitopes that rapidly accumulate variants
and those specific for epitopes that remain invariant can control
early viral replication. Knowledge of which populations of CD8 T
cells can best suppress viral replication is needed to design a T
cell-based vaccine.
It has been difficult to define whether acute-phase CD8 T
cell responses targeting invariant epitopes can establish control
of HIV replication. The development of individual epitope-
specific CD8 T cell responses is dependent on both the total
repertoire of HLA/major histocompatibility complex (MHC)
class I alleles in the host and the sequence of the infecting virus.
A “pre-escaped” HIV can be transmitted between individuals
who share a single HLA class I allele, but acute-phase CD8 T cell
responses that develop in the newly infected individual can still
select for escape variants in epitopes that did not accumulate
variants in the donor (7–9). Although the efficacy of acute-
phase CD8 T cell responses targeting invariant epitopes could
be measured when a pre-escaped HIV is transmitted between
fully HLA-identical people, this event is exceptionally rare.
Thus, it is nearly impossible to evaluate the in vivo antiviral
efficacy of acute-phase CD8 T cell responses that do not rapidly
select for variants in HIV-positive individuals.
Nonhuman primate studies with engineered SIV strains
containing point mutations in T cell epitopes can be used to
model the transmission of pre-escaped HIV. These studies typ-
ically focus on responses restricted by a single MHC class I
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allele, but CD8 T cell responses targeting epitopes restricted by
alternate MHC class I alleles can develop and rapidly select for
escape variants. Not surprisingly, control of pre-escaped SIV
replication has been inconsistent and unpredictable in these
studies (10–12) and the antiviral efficacy of acute-phase CD8 T
cell responses targeting invariant epitopes could not be evalu-
ated. Fully MHC class I-matched Mauritian cynomolgus ma-
caques (MCMs) infected with SIV can overcome these limita-
tions by mounting consistent CD8 T cell responses that select
for sequence variants in the same epitopes (13, 14). MCMs that
are homozygous for the M3 MHC class I haplotype are present
at a frequency of4% (15). There are now 14 known epitopes
restricted by MHC class I molecules encoded by the M3 haplo-
type (13, 16–18), of which 5 consistently accumulate sequence
variants within the first 12 weeks after SIVmac239 infection in
M3 homozygous MCMs. With such exquisite knowledge of
host MHC genetics and epitope-specific CD8 T cell immunity,
this model can be customized to evaluate the antiviral efficacy
of CD8 T cell responses that do not rapidly select for escape
variants.
We took advantage of the unique replication kinetics of the live
attenuated virus SIVmac239nef to understand the contribution
of CD8 T cell responses that do not rapidly select for escape vari-
ants on elite viral control. In Indian rhesus macaques and Mauri-
tian cynomolgus macaques infected with SIVmac239nef, an
acute-phase peak of virus replication is subsequently controlled to
levels that are not detectable with plasma viral load assays (19, 20).
Viral load decline is coincident with the emergence of CD8 T cell
responses (21, 22) and can be used as an indicator of T cell func-
tion.
We created an SIVmac239nef derivative, termedm3KOnef,
in which we ablated four of the five epitopes that accumulate vari-
ants within 12 weeks of SIVmac239 infection. The fifth epitope is
in an alternate reading frame and was undefined when we created
m3KOnef, so it remained intact. We eliminated one additional
well-characterized epitope in Pol that frequently accumulates
variants by 14 weeks after infection (18). M3 homozygous MCMs
in the acute phase of infection with m3KOnef are therefore ca-
pable of developing acute-phase CD8 T cell responses that target
less variable epitopes, making this the first model available to as-
sess the functional potency of these CD8 T cell responses to con-
trol early SIV replication. We found that M3 homozygous MCMs
could not control m3KOnef as well as MCMs that did not have
any of the MHC class I alleles present in the M3MHC haplotype.
These results provide compelling evidence that CD8 T cell re-
sponses that do not rapidly select for escape variants have limited
potency in vivo and argue that caution should be used when de-
signing vaccines to elicit T cell responses that target conserved
epitopes.
MATERIALS AND METHODS
Creation of virus stocks. The following clonal virus stocks were created for
this study: SIVmac239nef, barcoded SIVmac239nef (BCVnef), and
m3KOnef. For SIVmac239nef, we obtained the necessary plasmids con-
taining the 5= and 3= viral genomes (p239SpSp5= and pSIVmac239nef dele-
tionmutant) fromRonaldDesrosiers through the AIDSResearch andRefer-
ence Reagent Program, Division of AIDS, NIAID, NIH. The plasmid
containing the5=SIVgenomewith10 synonymous“barcoding”mutations in
Gag was used previously (12). For m3KOnef, we first identified consensus
variants that accumulated in virus populations replicating in M3 MCMs
during chronic SIVmac239 infection (15; data not shown). Twenty-three
substitutions were then incorporated into SIVmac239nef by custom gene
synthesis (GenScript, Piscataway, NJ) to create the 5= and 3= plasmids neces-
sary to construct m3KOnef. These plasmids were designed to include the
SphI restriction site required for coligation, and they contained long terminal
repeat sequences matching those in SIVmac239.
All virus stocks were created as described previously (23, 24). The
plasmids containing the 5= and 3= halves of the corresponding genomes
were digested with SphI, treated with shrimp alkaline phosphatase, pre-
cipitated, and then ligated together. Vero cells were transfected with the
ligated products and then cocultured with CEMx174 cells for 48 h. In-
fected CEMx174 cells were grown for about 1 week to produce high-titer
viruses. The p27 content of each virus stock was determined by enzyme-
linked immunosorbent assay (ELISA; ZeptoMetrix, Buffalo, NY) accord-
ing to themanufacturer’s protocol. The infectious titer of each virus stock
was determined by limiting-dilution inoculation of CEMx174 cells.
Briefly, cells were inoculated in quadruplicate with serial 4-fold dilutions
of virus stock, beginning at a 1:100 dilution. Two weeks later, individual
cultureswere scored as positive or negative for SIV infection by qualitative
p27 antigen capture ELISA (ZeptoMetrix). The infectious titer was then
estimated by using the proportionate-distance method of Reed and
Muench (25) and expressed in terms of 50% tissue culture infectious
doses (TCID50) per milliliter of virus stock.
In vitro coculture competition assays. All virus stocks were normal-
ized for a p27 content of 50 ng/ml. Viruses were mixed in the following
combinations: 2.5 ng m3KOnef or SIVmac239nef to 2.5 ng BCVnef
(1:1), 0.5 ngm3KOnef or SIVmac239nef to 4.5 ng BCVnef (1:9), and
4.5 ngm3KOnef or SIVmac239nef to 0.5 ngBCVnef (9:1). Each virus
mixture was incubated with 106 CEMx174 cells at 37°C for 4 h. After
washing, 5 105 cells were plated and grown for 1 week. Supernatant was
collected at days 3, 5, and 7.
The copy number of each virus was measured in the inoculum and in
each supernatant. Viral RNA was isolated with theM48 Biorobot appara-
tus (Qiagen, Valencia, CA). Quantification was conducted with the
SuperScript III Platinum One-Step quantitative PCR kit (Invitrogen,
Carlsbad, CA) as previously described (12). The SIVmac239nef and
m3KOnef viruses were quantified with primers and probes targeting an
84-bp region of gag (12, 26). BCVnef was quantified in a separate reac-
tion with a distinct set of primers and probes (12). The appropriate wild-
type or barcoded transcript was used for each standard curve. All compar-
ative reactions were run on the same plate with a Roche LightCycler 480
under the following conditions: cDNA synthesis at 50°C for 30 min, an
initial denaturation step at 95°C for 2 min, and 45 amplification cycles of
95°C for 10 s and 69°C for 30 s.
The ratio of m3KOnef or SIVmac239nef to BCVnef was deter-
mined for each sample and then normalized to the ratio that was present
in the inoculum. Replicative differences between viruses were assessed at
each time point with unpaired t tests (GraphPad Prism, La Jolla, CA). All
data were plotted on a log2 scale.
Animal care and use.MCMswere purchased fromCharles River Lab-
oratories and cared for by theWisconsin National Primate Research Cen-
ter according to protocols approved by theUniversity ofWisconsinGrad-
uate School Animal Care and Use Committee. Animals CY0348, CY0379,
CY0381, CY0382, CY0383, CY0384, and CY0385 were infected intrave-
nously with 10 ng of p27m3KOnef. Animals CY0332, CY0333, CY0334,
CY0335, CY0336, and CY0337 were infected intrarectally with 7,000
TCID50 of SIVmac239 as part of another study (13, 16). Animals CY0114,
CY0157, CY0160, CY0205, CY0206, CY0213, CY0338, CY0345, and
CY0386 were infected intravenously with 10 ng of p27 SIVmac239nef
(19).
Plasma viral loads analysis. Plasma SIV loads were determined es-
sentially as previously described (15, 26). Viral RNA was isolated from
plasma and then reverse transcribed and amplified with the Super-
Script III Platinum one-step quantitative reverse transcription (RT)-
PCR system (Invitrogen). Samples were quantified on a Roche Light-
Cycler 2.0 and compared to an internal standard curve on each run.
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The substitutions present in m3KOnef did not lie within the primer
or probe target sequence.
Differences in the log10 viral load set point were modeled by linear
mixed-effects regression with random effects for each animal and fixed
effects for each group. The mean log10 viral load set point for a group was
estimated by viral load measurements between weeks 14 and 20 after
infection. Themaximum log10 viral load before 5 weeks was defined as the
acute-phase peak viral load, and differences were modeled by linear re-
gression. Statistics and significance measures were calculated in R 2.15.2
with the lmer and gmodels packages.
Genome-wide sequencing of SIV and data analysis. Genome-wide
sequencing of replicating SIV was performed essentially as previously de-
scribed (13, 27). Viral RNA was isolated from plasma with the QIAamp
MinElute Virus Spin kit (Qiagen). The Superscript III One-Step RT-PCR
system with Platinum TaqHigh Fidelity (Invitrogen) was used to reverse
transcribe the viral RNA in four overlapping amplicons spanning the en-
tire SIV genome. PCR products were purified with the Qiagen MinElute
Gel Extraction kit (Qiagen) and quantified with the Quant-IT dsDNAHS
Assay kit (Invitrogen).
For pyrosequencing, libraries were prepared with the Nextera DNA
Sample Prep kit (Roche Titanium compatible; Epicentre, Madison,
WI) and 10-bp multiplex identifier tags were added. Tagged products
were purified twice with Agencourt AMPure XP beads (Beckman
Coulter Genomics, Danvers, MA) and then quantified with the
Quant-IT dsDNA HS Assay kit (Invitrogen) and the Agilent High Sen-
sitivity DNA kit (Agilent Technologies, Santa Clara, CA). Pyrose-
quencing was performed with a Roche/454 GS Junior instrument with
Titanium shotgun chemistry, according to the manufacturer’s proto-
cols (454 Life Sciences, Branford, CT).
Nucleotide variation relative to SIVmac239 was determined at each
position with Galaxy, an online tool used to analyze next-generation
sequence data (13, 28–30). FASTQ reads were trimmed, and low-qual-
ity uncertain sequences weremasked with an “N.” Sequence reads were
mapped to an SIVmac239 reference (accession no. M33262) with the
LASTZ algorithm. The SAM format was converted to a BAM format,
and a pileup was created. The total A, C, T, G, and N numbers at each
site were calculated. Sites that were greater than 1% variant from the
reference were assessed as synonymous or nonsynonymous with the
SNPeffect tool (31). Variants spanning nucleotide positions 1300 to
10200 with1% variation and greater than three times the percentage
of uncertain or indel sequences were plotted with GraphPad Prism.
Amino acid variation relative to SIVmac239 was determined as de-
scribed previously (13, 16). FASTQ reads were trimmed, and low-quality
sequences were masked with an “N.” FASTQ reads were converted to
FASTA reads and translated in all six reading frames. BLAT (BLAST-like
alignment tool) was used to align sequence reads with SIVmac239 pro-
teins at a minimum of 50% identity. Custom scripts were used to extract
the region of interest, remove reads with ambiguous sequences, andmea-
sure the frequency of each variant identified.
IFN- ELISPOT assays. Gamma interferon (IFN-) enzyme-linked
immunospot (ELISPOT) assays were performed as described previously
(15, 18). First, peripheral bloodmononuclear cells (PBMCs)were isolated
from EDTA-anticoagulated blood by Ficoll-Paque Plus (GE Healthcare,
Piscataway, NJ) density gradient centrifugation. A precoated monkey
IFN- ELISPOTplus plate (Mabtech, Mariemont, OH) was blocked, and
individual peptides were added to each well at a final concentration of 1
M. Each peptide was tested in duplicate, and concanavalin A (10 M)
was used as a positive control. Assays were performed according to the
manufacturer’s protocol, and wells were imaged with an AID ELISPOT
reader. The average number of spots per peptide was calculated, and we
subtracted the average number of spots formed with no peptide. Data
were extrapolated to 106 PBMCs to calculate the number of spot-forming
cells (SFCs) per 106 PBMCs.
Generation of peptide-specific T cell lines.T cell lines were grown as
described previously (17, 18). First, 5 106 PBMCs were isolated from
CY0381 and incubated with the immunogenic peptide (either
ARF129-43VY15 or ARF130-40QL11) for 1 week in medium supple-
mented with 5 105 U/ml of interleukin-2 (Prometheus Laboratories,
San Diego, CA). Restimulation was conducted every 1 to 2 weeks with
autologous irradiated B-lymphoblastoid cells pulsed with the relevant
peptide.
Intracellular cytokine staining. Activation of peptide-specific T
cells was measured via the production of IFN- and tumor necrosis
factor alpha (TNF-) as described previously (18). Briefly, peptide-
pulsed autologous B-lymphoblastoid cells were used to stimulate cul-
tured T cells at a 1:1 ratio for 4 h in the presence of brefeldin A (10
g/ml; Sigma-Aldrich). SingleMHC allele transferent cell lines, pulsed
with peptide and washed extensively, were used similarly to determine
MHC restriction. Cells were then stained with anti-CD8–PacBlue (BD
Biosciences, San Jose, CA) and anti-CD3–AF700 (BD Biosciences) an-
tibodies, fixed with 2% paraformaldehyde, and left at 4°C overnight.
On the following morning, the cells were permeabilized in 1% saponin
buffer, stained with anti-IFN-–fluorescein isothiocyanate (FITC)
(BD Biosciences) and anti-TNF-–phycoerythrin (PE) (BD Biosci-
ences) antibodies, washed in 1% saponin buffer, and fixed in 2% para-
formaldehyde. Flow cytometry was performed with an LSRII instru-
ment (BD Biosciences) and data were analyzed with FlowJo V.9.4.10
software (TreeStar Inc., Ashland, OR).
Tetramer staining. Fluorochrome-conjugatedMHC/peptide tetramers
were produced as described previously (32). The tetramers used in this study
were Mafa-A1*063/ARF130-40QL11-PE, Mafa-A1*063/Env338-346RF9-PE,
Mafa-B*075/Tat42-49QA8-PE, and Mafa-B*075/Rev59-68SP10-PE. Thawed
lymph node cells or PBMCs were stained with tetramer at 37°C for 20 min,
washed, and then stained with anti-CD3–AF700 (BD Biosciences), anti-
CD8–PacBlue (BD Biosciences), and anti-CD69–Texas Red–PE (Beckman
Coulter) antibodies. Flow cytometry was performed with an LSRII instru-
ment (BDBiosciences), anddatawereanalyzedwithFlowJoV.9.4.10software
(TreeStar Inc.). Tetramer-binding CD8 T cell frequencies were compared
between groups with paired or unpaired two-tailed t tests (GraphPad Prism)
after log transformation of the data.
Measurement of immune activation. Immune activation assays were
based on previous reports (33). Whole blood or cells isolated from bron-
choalveolar lavage (BAL) fluid were first incubated with surface stains.
Blood samples were then treated with FACSlyse, and BAL fluid samples
were treatedwith 2%paraformaldehyde. Cells were then permeabilized in
0.1% saponin buffer, stained with antibodies specific for intracellular
markers, washed, and analyzed by flow cytometry. The antibodies used
were anti-CD38–FITC (Stem Cell Technologies, Inc.), anti-CD4–PeCy7
(BD Biosciences), anti-CD3–PacBlue (BD Biosciences), anti-Ki-67–
AF647 (BD Biosciences), anti-CD20–AF700 (BioLegend), anti-CD8–
APCCy7 (BioLegend, San Diego, CA), and anti-CD69–Texas Red–PE
(Beckman Coulter, Indianapolis, IN).
RESULTS
Creation of an SIVmac239nef variant that is pre-escaped in
CD8Tcell epitopes.Wepreviously infected fourM3homozygous
MCMs with SIVmac239 and found that three of them established
high viral load set points (viral loads, 106 copies/ml) (15, 27).
Since few CD8 T cell epitopes restricted by molecules encoded by
the M3 MHC haplotype had been identified when we began this
study, we reasoned that high-frequency variants shared between
virus populations isolated from these three M3 homozygous
MCM progressors would have adequate replicative fitness and
contain effective escape mutations in commonly recognized CD8
T cell epitopes. We identified 23 shared, high-frequency nucleo-
tide variants that were nonsynonymous at 24 amino acid sites in
the nine main SIV reading frames and introduced these variant
nucleotides into SIVmac239nef (Fig. 1).We termed the resulting
virus m3KOnef to denote its origin as an SIVmac239nef deriv-
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ative specifically deficient in putative CD8 T cell epitopes re-
stricted by alleles present in the M3 MHC haplotype.
Fourteen CD8 T cell epitopes from SIVmac239 that are re-
stricted by MHC class I molecules encoded by the M3MHC hap-
lotype were subsequently identified (16, 17), including one
epitope defined in this study that is derived from a cryptic open
reading frame (see Fig. S1 in the supplemental material). Five of
these epitopes (Gag386-394GW9, Pol592-599QP8, Rev59-68SP10,
Nef103-111RM9, and Nef196-203HW8) were disrupted with five of
the nucleotide substitutions and the deletion in nef (Fig. 1A). All
five of these epitopes accumulate variants by 14 weeks after SIV-
mac239 infection inM3 homozygousMCMs (13, 16, 18). Accord-
ingly, we could determine whether MCMs could control the rep-
lication of attenuated SIV in the absence of CD8 T cell responses
targeting five epitopes that escape during the acute phase of infec-
tion.
We reasoned that there were nine epitopes restricted by
MHC class I molecules encoded by the M3 haplotype that were
intact in m3KOnef. Of these nine epitopes, the cryptic
epitope (ARF130-40QL11) was the only one that accumulated
variants by 12 weeks after SIVmac239 infection. This left eight
epitopes that elicit CD8 T cell responses that do not commonly
select for variants during the acute phase of SIVmac239 infec-
tion. Accordingly, we could determine whether CD8 T cell re-
sponses targeting the remaining intact epitopes could effec-
tively control replication of m3KOnef. The additional 19
nucleotide substitutions that were introduced to create
m3KOnef were typically found in virus populations replicat-
ing in SIVmac239-infected M3 homozygous MCMs, but the
role of these other variants is unknown.
We tested the fitness of m3KOnef by using in vitro coculture
competition assays with a barcoded SIVmac239nef (BCVnef)
(12). Our data indicated that the mutations we incorporated into
SIVmac239nef to create m3KOnef did not decrease viral fit-
ness in vitro (see Fig. S2 in the supplemental material). In fact,
m3KOnef appeared to replicate slightly more efficiently than
SIVmac239nef in vitro.
M3 homozygous MCMs do not control replication of
m3KOnef.We infected four M3 homozygous MCMs and three
MHC-mismatched MCMs with m3KOnef (Table 1). M3 ho-
mozygous animals only express MHC alleles present in the M3
MHC haplotype. None of themajorMHC class I alleles present in
the MHC-mismatched MCMs are present in the M3 haplotype
(34). Most of the animals in the MHC-diverse group expressed
MHC alleles that are also present in the M3 MHC haplotype, but
none were M3 homozygotes. Although a group of M3 homozy-
gousMCMs infected with SIVmac239nef would have been valu-
able for direct comparison, we were unable to obtain this addi-
tional group for our study.
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FIG 1 Amino acid sequence differences between SIVmac239 and m3KOnef. Twenty-three nucleotide mutations that affected 24 amino acid sites were
engineered into SIVmac239nef to create m3KOnef. The SIV proteins and the amino acid positions affected are shown. Dots represent identity, and capital
letters represent amino acid differences. The underlined letter in light gray indicates a nucleotide change that was synonymous with respect to that specific
protein. (A) Substitutions engineered into epitopes restricted by MHC class I molecules encoded by the M3 MHC haplotype are shown. (B) Additional
substitutions outside known epitopes are shown.
TABLE 1 Animals used in this study
Animal no. MHC genotype Infecting virus
CY0379 M3/M3 m3KOnef
CY0381 M3/M3 m3KOnef
CY0384 M3/M3 m3KOnef
CY0385 M3/M3 m3KOnef
CY0348 M4/M4 m3KOnef
CY0382 M4/M5 m3KOnef
CY0383 M4/M7 m3KOnef
CY0332 M3/M3 SIVmac239
CY0333 M3/M3 SIVmac239
CY0334 M3/M3 SIVmac239
CY0335 M3/M3 SIVmac239
CY0336 M3/M3 SIVmac239
CY0337 M3/M3 SIVmac239
CY0114 M1/M3 SIVmac239nef
CY0157 M1/M1 SIVmac239nef
CY0160 M1/M2 SIVmac239nef
CY0205 M1/M3 SIVmac239nef
CY0206 M1/M3 SIVmac239nef
CY0213 M1/M3 SIVmac239nef
CY0338 M1/M2 SIVmac239nef
CY0345 M1/M3 SIVmac239nef
CY0386 M1/M3 SIVmac239nef
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We observed a small increase in the peak plasma viremia of
m3KOnef in M3 homozygous MCMs compared to the peak
viremia of SIVmac239nef in MHC-diverse MCMs (P 	 0.03,
Fig. 2 and Table 2). There were no other significant differences
between the peak viral loads. The similar peak viremias observed
in the MHC-mismatched MCMs infected with m3KOnef and
the MHC-diverse MCMs infected with SIVmac239nef suggest
that themutationswe incorporated into SIVmac239nef to create
m3KOnef did not reduce viral fitness in vivo.
The mean viral load set point established between 14 and 20
weeks after infection was significantly higher in the M3 homozy-
gous MCMs than in the MHC-mismatched MCMs infected with
m3KOnef (P 
 0.001, Fig. 2 and Table 3), demonstrating that
M3 homozygous MCMs are unable to control m3KOnef repli-
cation. Although the mean viral load set point was higher in the
MHC-mismatched MCMs infected with m3KOnef than in his-
torical control MCMs infected with SIVmac239nef (P	 0.058,
Fig. 2 and Table 3; David O’Connor and Justin Greene, personal
communication), these were not significantly different. Thus,
suppression of m3KOnef replication can occur in animals with-
out M3 MHC class I alleles.
FIG 2 Virus replication is not controlled in M3 homozygous MCMs infected with m3KOnef. Viral loads were measured for 20 weeks after infection of the
following groups: M3 homozygous MCMs infected with m3KOnef (blue), MHC-mismatched MCMs infected with m3KOnef (green), and MHC-diverse
MCMs infected with SIVmac239nef (black). All MHC genotypes are shown in Table 1. Log10 viral load trajectories are shown for each individual (thin lines)
and each group (smoothed, heavy lines). Viral load set point estimates and 95% confidence intervals for each group are represented by short vertical bars (see
Table 2 for statistics). The tall vertical black line is a reference point at 14 weeks after infection.
TABLE 2 Peak viral loads in groups of animals infected with different
strains of attenuated SIV
Group (no. of animals)
Peak viral
load (log10)
95% CIa (log10)
Lower Upper
M3 homozygous MCMs infected with
m3KOnef (4)
5.78b 5.23 6.32
MHC-mismatched MCMs infected with
m3KOnef (3)
5.53 4.98 6.08
MHC-diverse MCMs infected with
SIVmac239nef (8)
5.02 4.63 5.41
a CI, confidence interval.
b M3 homozygous MCMs infected with m3KOnef versus MHC-diverse MCMs
infected with SIVmac239nef, P	 0.03.
TABLE 3 Mean viral load set points in groups of animals infected with
different strains of attenuated SIV
Group (no. of animals)
Mean viral load
set point (log10)
95% CIa (log10)
Lower Upper
M3 homozygous MCMs infected
with m3KOnef (4)
3.31b,c 2.70 3.90
MHC-mismatched MCMs infected
with m3KOnef (3)
1.59d 0.86 2.37
MHC-diverse MCMs infected with
SIVmac239nef (8)
0.78 0.34 1.25
a CI, confidence interval.
b M3 homozygous MCMs infected with m3KOnef versus MHC-diverse MCMs
infected with SIVmac239nef, P
 0.001.
c M3 homozygous MCMs infected with m3KOnef versus MHC-mismatched MCMs
infected with m3KOnef, P
 0.001.
d MHC-mismatched MCMs infected with m3KOnef versus MHC-diverse MCMs
infected with SIVmac239nef, P	 0.058.
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We measured the depletion of peripheral CD4 T cells after
infection with m3KOnef in all seven animals. In contrast to the
preservation of peripheral CD4 T cells in macaques infected with
SIVmac239nef (35, 36), we found that peripheral CD4 T cell
levels declined during the acute phase of infection in all of the
animals, independently of the MHC genotype, and then re-
bounded (Fig. 3).
We also observed greater frequencies of CD4 and CD8 T cells in
the BAL fluid and blood samples that were both CD38 and Ki67
during the acute m3KOnef infection phase than in those animals
infected with SIVmac239nef (see Table S1 and Fig. S3 in the sup-
plemental material). This was most apparent in cells isolated from
BAL fluid at 14 days after infection. These data provide evidence that
there was greater immune activation in the animals infected with
m3KOnef than in animals infected with SIVmac239nef. This was
not surprising, as high levels of immune activation have been ob-
served during the acute phase of viral infection (37, 38). Even though
our data suggest that m3KOnef was potentially more pathogenic
than SIVmac239nef, replication of m3KOnef was more suscepti-
ble to host immune responses in animals without M3 MHC alleles
than in those animals withM3MHC alleles.
Detection of CD8 T cell responses in the blood and lymph
nodes of MCMs infected with m3KOnef. We next examined
which epitopes were targeted by acute-phase CD8 T cell responses
in M3 homozygous MCMs infected with m3KOnef in the pe-
ripheral blood and lymph nodes. As expected, CD8 T cell re-
sponses targeting the five epitopes thatwere ablated inm3KOnef
were undetectable at 3 weeks after m3KOnef infection, as mea-
sured by IFN- ELISPOT assays with PBMCs and tetramer stain-
ing of cells isolated from lymph nodes (Fig. 4 and 5D). These
same animals, however, had acute-phase CD8 T cell responses
targeting two alternate CD8 T cell epitopes (Env338-346RF9 and
Tat42-49QA8) that typically do not accumulate variants until the
chronic infection phase (Fig. 4 and 5A and B) (27). We also de-
tected CD8 T cells in lymph nodes targeting the ARF130-40QL11
cryptic epitope (Fig. 5C) that was identified in this study (see Fig.
S1 in the supplemental material). The detection of three acute-
phase CD8 T cell responses in M3 homozygous MCMs infected
with m3KOnef demonstrated that the remaining intact immu-
nogenic epitopes had the potential to elicit epitope-specific CD8T
cell responses restricted by M3-encoded MHC class I molecules.
Two of these responses typically do not rapidly select for escape
variants during infection with SIVmac239, and the third response
targets a cryptic epitope.
Sequence variants accumulate more rapidly in the Env338-346RF9
and ARF130-40QL11 epitopes after infection with m3KOnef.
Next, we asked whether the selection of viral variants was acceler-
ated in the three epitopes (Env338-346RF9, Tat42-49QA8, and
ARF130-40QL11) targeted during the acute m3KOnef infection
phase. We deep sequenced the entire SIV coding region in M3
homozygous MCMs infected with m3KOnef at 3 and 12 weeks
after infection (see Tables S2 and S3 in the supplemental material)
and compared the data to the sequences of virus populations iso-
lated fromM3 homozygous MCMs at 4 and 12 weeks after infec-
tion with SIVmac239 (13). Very few variants were detected in the
Env338-346RF9 epitope in virus populations isolated from M3
homozygous MCMs at week 3 after infection with m3KOnef
(Fig. 6A), but substantial variation was apparent after 12 weeks
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FIG 3 CD4 T cell counts in MCMs infected with m3KOnef. PBMCs were stained during the first 20 weeks after infection with m3KOnef with anti-CD3,
-CD4, -CD8, -CD95, and -CD28 antibodies. Samples were analyzed by flow cytometry. Absolute counts are shown for the whole CD4 T cell compartment and
various CD4 T cell subsets, as indicated.
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(Fig. 6B). In contrast, variants were still not detected in the
Env338-346RF9 epitope by 12weeks after infectionwith SIVmac239
(Fig. 6C). We did not detect variation within the Tat42-49QA8
epitope in virus populations isolated from animals infected with
either m3KOnef or SIVmac239 by 12 weeks after infection (data
not shown).
Interestingly, we detected variation within the ARF130-40QL11
epitope in M3 homozygous MCMs at 3 weeks after infection with
m3KOnef (Fig. 7A). This time frame was on a par with the rapid
accumulation of variants detected in several of the epitopes that
were disrupted in m3KOnef (13). In M3 homozygous MCMs
infected with SIVmac239, we found that this epitope did not
accumulate variants 4 weeks after infection (Fig. 7B), although
substantial variation was apparent after 12 weeks (Fig. 7C). Un-
fortunately, we did not remove the ARF130-40QL11 epitope in our
pre-escaped virus because we did not know it existed when we
began the project. Nonetheless, variant accumulation in this
epitope was more rapid in M3 homozygous MCMs infected with
m3KOnef than in MHC-matched animals infected with SIV-
mac239.
In addition, we sequenced virus populations isolated from
MCMs at 3 weeks after infection with SIVmac239nef. We did
not find any nonsynonymous variants present at a frequency
greater than 20% (see Fig. S4 in the supplemental material). Viral
loads were too low for sequencing at later time points. With such
rapid viral control, the absence of variants in these virus popula-
tions at this early time point was not surprising. We expect that
variants will accumulate in SIVmac239nef over time, as detected
previously by others (19, 39).
Notably, we did not detect reversion of the engineered muta-
tions in virus populations isolated from any of the animals by 3
weeks after infection with m3KOnef, and there was minimal
reversion by 12 weeks in the M3 homozygotes (see Fig. S5 and S6
in the supplementalmaterial). The stability of the engineered sub-
stitutions further suggests that the variants introduced were not
deleterious to viral replication.
DISCUSSION
In the present study, we took advantage of MHC-identical
MCMs to study CD8 T cell-mediated control of live attenuated
SIV replication, an MHC-independent model of elite control.
We created a derivative of SIVmac239nef incorporating
commonly detected nucleotide substitutions identified in vi-
rus populations replicating in M3 homozygous MCMs. In
m3KOnef, we ablated five epitopes that all accumulate vari-
ants by 14 weeks after SIVmac239 infection of M3 homozygous
MCMs. Even though CD8 T cell responses targeting these five
epitopes were absent, we detected reproducible CD8 T cell re-
sponses targeting three additional epitopes that remained in-
tact in m3KOnef, two of which typically do not select for
escape variants until the chronic infection phase in M3 ho-
mozygous MCMs infected with SIVmac239. Replication of
m3KOnef was not controlled in M3 homozygous animals,
suggesting that the set of CD8 T cell responses that predomi-
nated in M3 homozygous MCMs during the acute phase of
infection with m3KOnef and do not tend to rapidly select for
escape variants were unable to control viral replication.
The key observation in this study is that control of live attenu-
ated SIV replication is strongly associatedwith acute-phase CD8T
cell responses that rapidly select for sequence variants. We found
that CD8 T cell responses that do not typically select for escape
variants during the first few weeks of SIV infection were insuffi-
cient to control the replication of m3KOnef. In contrast,
m3KOnef replication was controlled in animals with entirely
different MHC class I alleles, enabling the presentation of alter-
nate epitopes. These results suggest that the CD8 T cell responses
that typically emerge during the chronic infection phase and do
not rapidly select for escape variants are collectively less potent
than the acute-phase CD8 T cell responses that do rapidly select
for escape variants.
An alternate explanation for these results is that acute-phase
CD8 T cell responses target some epitopes that do rapidly ac-
cumulate variants and some that do not. By specifically elimi-
nating the responses that do select for escape variants, we in-
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advertently reduced the effective breadth of the acute-phase
CD8 T cell response, thus reducing viral control. We do not
favor this interpretation because we have not observed the en-
tire array of CD8 T cell responses in peripheral blood during
the acute phase of infection of M3 homozygous MCMs with
SIVmac239 (13, 16); several responses are detectable only later
in infection. It is possible that these responses are exerting an
antiviral effect that is not detectable by our immunological
assays, but this seems unlikely.
Wealsodetectedacceleratedvariationkinetics in theARF130-40QL11
and Env338-346RF9 epitopes when CD8 T cell responses targeting
these epitopes were present at a high frequency at or near the time
of peak viral replication. It is reasonable to suggest that the rapid
selection of these epitope variants could be attributed to higher
viral replication at the time the CD8 T cell responses were present
rather than as a function of enhanced epitope-specific CD8 T cell
potency. Indeed, this observation suggests that the correlation
between CD8 T cell potency and the selection of escape variants is
not absolute. Thus, CD8 T cells that select for escape variants are
not always the most potent; however, CD8 T cells that are potent
do tend to select for sequence variants. In other words, rapid vari-
ation is not sufficient by itself to implicate a specific CD8 T cell
response in protective immunity, but this approach can be used as
an initial filter to identify potent CD8 T cell responses. Further
studies are needed to evaluate whether CD8 T cell responses tar-
geting different epitopes throughout infection are functionally
different and, consequently, have distinct abilities to destroy vi-
rus-infected cells.
There are two important caveats to this study. First, the animal
groups used were necessarily small. While we dedicated consider-
able resources to assembling a cohort of M3 homozygous MCMs
to challenge with m3KOnef, we were unable to assemble a sim-
ilarly sized cohort of M3 homozygous MCMs to challenge with
SIVmac239nef. We now know that M3 homozygous animals
generally exhibit high viral loads when challenged with SIV-
mac239 (15, 16), sowe cannot formally exclude the possibility that
MCMs with this genotype are predisposed to higher viral loads
when infected with any SIV strain. Nonetheless, the nearly uni-
form complete control of SIVmac239nef replication in both In-
dian rhesus and Mauritian cynomolgus macaques (19, 20) (Fig.
2), irrespective of MHC background, makes this unlikely. In ad-
dition to the small group sizes, our m3KOnef controls were not
MHC identical to one another. The onlyMCMhaplotypes that do
not share any MHC class I alleles with the M3 haplotype are rare
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FIG 5 CD8 T cells detected in M3 homozygous MCMs during the acute m3KOnef infection phase target different epitopes compared to the acute phase of
SIVmac239 infection. MHC/peptide tetramers presenting four SIVmac239-derived epitopes were used to quantify the percentage of antigen-specific CD3
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shown.
Harris et al.
9360 jvi.asm.org Journal of Virology
(34), so animals that are fully MHC identical for these alternate
haplotypes are exceptionally uncommon. Even though the animal
numbers were small, we believe that the use of fully MHC-identi-
cal, M3 homozygous MCMs infected with m3KOnef provides
the best cohort used to date to specifically study the in vivo anti-
viral efficacy of CD8 T cell responses that do not rapidly select for
escape variants.
Second, we recognize that our results are confounded some-
what by the unexpectedly strong response to the cryptic
ARF130-40QL11 epitope. On the basis of our classification of
early T cell responses that rapidly select for sequence variants,
we would ablate this epitope in the pre-escaped virus if we
repeated this study.We did not include ARF130-40QL11 epitope
variants in m3KOnef because we originally identified com-
mon variants that were nonsynonymous in the nine main SIV
genes; we did not consider cryptic epitopes. Still, the presence
of acute-phase CD8 T cells targeting ARF130-40QL11 was insuf-
ficient to enable control of m3KOnef in M3 homozygous
MCMs. It is provocative to consider that control of m3KOnef
may have been even weaker in the absence of responses target-
ing ARF130-40QL11.
The limited potency of acute-phase CD8 T cell responses tar-
geting epitopes that do not rapidly accumulate variants calls into
question the value of designing HIV vaccines to elicit CD8 T cell
responses targeting conserved elements in the viral proteome.
Conserved-element vaccines are attractive because the immuno-
genic sequences targeted by vaccine-specific immune responses
should be present in most circulating virus populations (6, 40–
42). Unfortunately, T cell responses targeting conserved or invari-
ant epitopes are also typically subdominant in HIV infection (43).
Our data suggest that these responses are not particularly effective
for long-term control of viral replication, but we do not know
whether CD8 T cell responses targeting epitopes that are even less
variable than the ones studied here could effectively control viral
replication.With theMCMmodel, we can repeat the strategy used
to generate m3KOnef and serially ablate additional epitopes re-
stricted byM3MHC alleles. Given enough generations, we expect
to elicit acute-phase CD8 T cell responses targeting epitopes that
are practically invariant or potentially eliminate the entire set of
CD8 T cell responses (27). Ultimately, challenging M3 homozy-
gous MCMs with a “T cell epitope-deficient virus” could help
quantify the requirement for CD8 T cell responses with reference
to MHC-independent viral control.
Overall, the observations from this SIV model can be ap-
FIG 6 Accumulation of sequence variants in Env338-346RF9 is more rapid in M3 homozygous MCMs infected with m3KOnef than in those infected with
SIVmac239. Viruses replicating inM3 homozygousMCMs at 3 weeks afterm3KOnef infection (A), 12 weeks afterm3KOnef infection (B), and 12weeks after
SIVmac239 infection (C) were subjected to genome-wide sequencing by Roche/454 pyrosequencing. Amino acid variants in Env338-346RF9 were investigated as
described in Materials and Methods. The wild-type sequence and animal identification numbers are shown at the top of each panel. Masked identical bases are
represented by dots, and amino acid replacements are represented by capital letters. The frequency of each epitope variant sequence is shown. A variant sequence
had to be present in at least one animal at a frequency of 1% or greater to be included in the graphic. The legend indicates the color associated with a given variant
frequency. A zero indicates that no reads were detected with that sequence.
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plied to our understanding of the complex interplay between
host immune responses and viral evolution at the population
level. As HIV continues to adapt to common HLA alleles in the
population, the most potent epitopes may not be immunogenic
in transmitted HIV strains, such that alternate CD8 T cell re-
sponses targeting less variable epitopes will predominate dur-
ing the acute phase of infection. This might ultimately lead to
less efficient viral control and accelerated disease progression,
an alarming forecast with significant implications for the fu-
ture of the HIV epidemic.
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